ticagrelor or prasugrel .

Phase 3Small molecule

FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

ticagrelor or prasugrel . is one of 26 small molecule programs targeting Aneurysm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AneurysmRecruiting

AneurysmPhase 3

Recruiting

Competition

Competitive Landscape

32 competitors in Aneurysm

#DrugCompanyPhaseTrials

Keppra

UCB

Approved

2 2

Medrol

Pfizer

Approved

2 3

Plavix

Sanofi

Approved

2 4

Tecfidera

Biogen

Approved

1 5

Aggrastat

MMedicure

Approved

2 6

Xarelto

WWim Janssens

Approved

1 7

Effient

CCosette Pharmaceuticals, Inc.

Approved

1 8

Pletal

Otsuka

Approved

1 9

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 10

Coumadin

AAbbott

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalRecruiting

Aneurysm

NCT06400940

Clinical

Trials by Indication[1]

Aneurysm1 trial

Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

Recruiting·FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·Phase 4·NCT06400940·640 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ticagrelor or prasugrel .. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ticagrelor or prasugrel . compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ticagrelor or prasugrel .. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

ticagrelor or prasugrel .

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Aneurysm1 trial

References

Drug Info

Quick Facts

Related News